Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005
The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2 Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019